JSW
SUPN icon

Journey Strategic Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Journey Strategic Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236K Buy
4,562
+111
+2% +$5.65K 0.01% 686
2025
Q4 		$221K Sell
4,451
-4
-0.1% -$194 0.01% 671
2025
Q3 		$213K Buy
+4,455
New +$179K 0.01% 641

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Journey Strategic Wealth's SUPN Position: Q1 2026 in Review

Journey Strategic Wealth increased its Supernus Pharmaceuticals (SUPN) stake by 2.5% in Q1 2026, buying an estimated $5.65K and bringing the position to 4,562 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #686.

Journey Strategic Wealth first reported a position in SUPN in Q3 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Journey Strategic Wealth held 4,562 shares of Supernus Pharmaceuticals worth $236K as of Q1 2026.
  • Journey Strategic Wealth bought 111 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.65K.
  • Supernus Pharmaceuticals made up 0.01% of Journey Strategic Wealth's portfolio in Q1 2026, its #686 holding.
  • Journey Strategic Wealth first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.